1. Home
  2. LNZA vs MDXH Comparison

LNZA vs MDXH Comparison

Compare LNZA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LanzaTech Global Inc.

LNZA

LanzaTech Global Inc.

N/A

Current Price

$6.11

Market Cap

77.5M

Sector

Industrials

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$0.58

Market Cap

68.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LNZA
MDXH
Founded
2005
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
77.5M
68.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
LNZA
MDXH
Price
$6.11
$0.58
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.80
AVG Volume (30 Days)
46.8K
★ 200.4K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 17.00
N/A
Revenue
★ $55,845,000.00
N/A
Revenue This Year
N/A
$5.40
Revenue Next Year
N/A
$12.92
P/E Ratio
$0.36
★ N/A
Revenue Growth
★ 12.61
N/A
52 Week Low
$5.02
$0.40
52 Week High
$44.00
$5.33

Technical Indicators

Market Signals
Indicator
LNZA
MDXH
Relative Strength Index (RSI) 50.45 43.06
Support Level $5.53 $0.51
Resistance Level $6.45 $0.64
Average True Range (ATR) 0.28 0.04
MACD 0.02 -0.00
Stochastic Oscillator 55.17 44.87

Price Performance

Historical Comparison
LNZA
MDXH

About LNZA LanzaTech Global Inc.

LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: